Get Ready for Hep C Meds Maviret and Vosevi

You'll see big changes in treating hepatitis C due to the new oral antivirals, Maviret and Vosevi.

Maviret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

It'll also be the lowest priced option at about $43,000/course...compared to $68,000 for Harvoni or $61,000 for Epclusa for 12 weeks.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote